Sector Update: Health Care Stocks Slumping Near Friday Close
4:00PM ET 1/07/2022 MT NewswiresHealth care stocks turned narrowly lower this afternoon, with the NYSE Health Care Index slipping 0.2% and the SPDR Health Care Select Sector ETF (XLV)...
Quotes Snapshot > CYTK
Cytokinetics Inc CYTK:NASDAQ
Last Price$30.30NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$26.95 (2)
Ask (Size)$33.56 (2)
Day Low / HighN/A - N/A
Volume1.5 M
Read more news Recent News
Sector Update: Health Care Stocks Nearing Break-Even Mark Following Afternoon Uptick
1:52PM ET 1/07/2022 MT NewswiresHealth care stocks have turned narrowly mixed this afternoon, with the NYSE Health Care Index rising less than 0.1% while the SPDR Health Care Select...
Sector Update: Health Care Stocks Retreat Premarket Friday
9:16AM ET 1/07/2022 MT NewswiresHealth care stocks were retreating premarket Friday. The iShares NASDAQ Biotechnology Index (IBB) was 0.24% lower while the Health Care SPDR (XLV) was...
Cytokinetics Secures Up to $450 Million in Funding From Royalty Pharma for Heart Disease Drug Candidates
8:22AM ET 1/07/2022 MT NewswiresCytokinetics (CYTK) said Friday it has secured funding of up to $450 million from Royalty Pharma (RPRX) for the potential commercialization of omecamtiv...
View all Commentary and Analysis
The 1-Minute Market Report - January 8, 2022
1:35AM ET 1/10/2022 Seeking AlphaCytokinetics: Biotech That Should Be On Your Radar With Several Catalysts In 2022
7:51PM ET 1/07/2022 Seeking AlphaWeek In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
1:45AM ET 12/27/2021 Seeking AlphaIBB And XBI: 4 Reasons To Buy Biotech Stocks Ahead Of 2022
8:33AM ET 12/06/2021 Seeking AlphaCompany Profile
Business DescriptionCytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 280 East Grand Avenue South San Francisco, California 94080 |
| Phone | +1.650.624.3000 |
| Number of Employees | 130 |
| Recent SEC Filing | 01/07/2022 8-K |
| President, Chief Executive Officer & Director | Robert I. Blum |
| Vice President-Development Operations | Eric Terhaerdt |
| Chief Financial Officer & Senior Vice President | Ching W. Jaw |
| Executive Vice President-Research & Development | Fady Ibraham Malik |
Company Highlights
| Price Open | $30.52 |
| Previous Close | $30.81 |
| 52 Week Range | $17.72 - 47.90 |
| Market Capitalization | $2.5 B |
| Shares Outstanding | 83.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/24/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$3.08 |
| Beta vs. S&P 500 | N/A |
| Revenue | $31.5 M |
| Net Profit Margin | -1,061.13% |
| Return on Equity | -204.75% |
Analyst Ratings as of 01/06/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |